J&J releases the first big data cut in the RSV vaccine race, setting bar for GlaxoSmithKline and Pfizer
The world’s largest vaccine companies — and some ambitious biotechs — have been racing for years now to develop an inoculation for RSV, one of the deadliest seasonal viruses of the pre-Covid era. Data on any of the experimental jabs, though, have been slow coming.
On Sunday, however, J&J announced in a large mid-stage trial that its RSV vaccine was 80% effective at preventing infections that required medical attention in adults over 65. It was 70% effective against preventing any type of symptomatic infection.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,700+ biopharma pros reading Endpoints daily — and it's free.